Thrombotic Microangiopathy in Transplantation and Malignancy

Lirong Qu; Joseph E. Kiss

doi:10.1055/s-2005-925475

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2005; 31(6): 691-699
DOI: 10.1055/s-2005-925475

Thrombotic Microangiopathy in Transplantation and Malignancy

Lirong Qu¹ , Joseph E. Kiss²

¹Institute for Transfusion Medicine and Department of Pathology, University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
²Associate Professor, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Abstract

ABSTRACT

Thrombotic microangiopathy (TMA) after hematopoietic stem-cell transplantation (HSCT) or solid-organ transplantation is a serious complication that may be associated with diverse clinical conditions. The reported incidence varies widely, in part due to different diagnostic criteria. Currently, the diagnosis is based mostly on clinical features and is often uncertain; many disease or therapy-related complications in transplantation and malignancy can manifest clinical features of TMA. Risk factors for TMA post HSCT include the type of conditioning regimen, the presence graft-versus-host disease (GVHD), the use of calcineurin inhibitors (cyclosporine and tacrolimus) for GVHD prophylaxis, and infection. Cyclosporin and tacrolimus are the most commonly reported agents associated with TMA in solid-organ (mainly kidney) transplantations. Cancer-related TMA may be associated with chemotherapy or the malignancy itself. Compared with idiopathic TMA (thrombotic thrombocytopenic purpura), the outcome for patients with TMA post-HSCT or disseminated malignancy is poor. The efficacy of plasma exchange in the treatment of TMA post-HSCT or malignancy is uncertain. In the future, objective criteria integrating laboratory features (including tissue pathology, quantitative hematology, and endothelial cell functionality) with clinical features may assist in the diagnostic accuracy of TMA post HSCT, which would allow better evaluation of treatment modalities and better prediction of prognosis and outcomes.

KEYWORDS

Thrombotic microangiopathy - thrombotic thrombocytopenic purpura (TTP) - hemolytic uremic syndrome (HUS) - hematopoietic stem cell - cancer - drugs

Volltext

Referenzen

REFERENCES

1 George J N, Li X, McMinn J R et al.. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004; 44 294-304
2 Holler E, Kolb H J, Moller A et al.. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990; 75 1011-1016
3 Zeigler Z R, Shadduck R K, Nemunaitis J, Andrews D F, Rosenfeld C S. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant. 1995; 15 247-253
4 Kanamori H, Takaishi Y, Takabayashi M et al.. Clinical significance of fragmented red cells after allogeneic bone marrow transplantation. Int J Hematol. 2003; 77 180-184
5 Pettitt A R, Clark R E. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant. 1994; 14 495-504
6 Nishida T, Hamaguchi M, Hirabayashi N et al.. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant. 2004; 33 1143-1150
7 Shidham V B, Chang C C, Shidham G et al.. Colon biopsies for evaluation of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients. BMC Gastroenterol. 2003; 3 5
8 Roy V, Rizvi M A, Vesely S K, George J N. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant. 2001; 27 641-646
9 Paquette R L, Tran L, Landaw E M. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant. 1998; 22 351-357
10 Iacopino P, Pucci G, Arcese W et al.. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant. 1999; 24 47-51
11 Fuge R, Bird J M, Fraser A et al.. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001; 113 58-64
12 Sarode R, McFarland J G, Flomenberg N et al.. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995; 16 271-275
13 Ruutu T, Hermans J, Niederwieser D et al.. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002; 118 1112-1119
14 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc. 2003; 78 421-430
15 Daly A S, Hasegawa W S, Lipton J H, Messner H A, Kiss T L. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apheresis Sci. 2002; 27 3-12
16 Hahn T, Alam A R, Lawrence D et al.. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation. 2004; 78 1515-1522
17 Shimoni A, Yeshurun M, Hardan I et al.. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced. Biol Blood Marrow Transplant. 2004; 10 484-493
18 Uderzo C, Fumagalli M, De Lorenzo P et al.. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant. 2000; 26 1005-1009
19 Schriber J R, Herzig G P. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997; 34 126-133
20 Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Hemolytic uremic syndrome after allogeneic or autologous hematopoietic stem cell transplantation for childhood malignancies. Bone Marrow Transplant. 1998; 21 281-286
21 Waiser J, Budde K, Rudolph B, Ortner M A, Neumayer H H. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis. 1999; 34 556-559
22 Matsuda Y, Hara J, Miyoshi H et al.. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children. Bone Marrow Transplant. 1999; 24 919-923
23 Fassas A B, Buddharaju L N, Rapoport A et al.. Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation. Leuk Lymphoma. 2001; 42 801-804
24 Takatsuka H, Wakae T, Toda A et al.. Association of Helicobacter pylori with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation. Clin Transplant. 2004; 18 547-551
25 Plews D E, Turner M L, Wallace W H. Plasma exchange as successful treatment of thrombotic thrombocytopenic purpura post autologous bone marrow transplant in a child. Bone Marrow Transplant. 2000; 25 679-680
26 Furlan M, Robles R, Solenthaler M et al.. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997; 89 3097-3103
27 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339 1585-1594
28 van der Plas R M, Schiphorst M E, Huizinga E G et al.. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999; 93 3798-3802
29 Allford S L, Bird J M, Marks D I. Thrombotic thrombocytopenic purpura following stem cell transplantation. Leuk Lymphoma. 2002; 43 1921-1926
30 Arai S, Allan C, Streiff M et al.. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J. 2001; 2 292-299
31 Vesely S K, George J N, Lammle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102 60-68
32 Daly A S, Xenocostas A, Lipton J H. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant. 2002; 30 709-715
33 Dlott J S, Danielson C F, Blue-Hnidy D E, McCarthy L J. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004; 8 102-111
34 Diamant M, Tushuizen M E, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease?. Eur J Clin Invest. 2004; 34 392-401
35 Jimenez J J, Jy W, Mauro L M, Horstman L L, Ahn Y S. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol. 2001; 112 81-90
36 Jy W, Jimenez J J, Mauro L M et al.. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost. 2005; 3 1301-1308
37 Takatsuka H, Wakae T, Mori A et al.. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002; 29 907-911
38 Bernardo A, Ball C, Nolasco L, Moake J F, Dong J F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104 100-106
39 Nabhan C, Kwaan H C. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am. 2003; 17 177-199
40 Chopra R, Eaton J D, Grassi A et al.. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000; 111 1122-1129
41 Corti P, Uderzo C, Tagliabue A et al.. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002; 29 542-543
42 Rock G A, Shumak K H, Buskard N A et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991; 325 393-397
43 Rock G A. Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000; 109 496-507
44 Teruya J, Styler M, Verde S, Topolsky D, Crilley P. Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation. J Clin Apheresis. 2001; 16 169-174
45 Milone J, Napal J, Bordone J, Etchegoyen O, Morales V. Complete response in severe thrombotic microangiopathy post bone marrow transplantation (BMT-TM) after multiple plasmaphereses. Bone Marrow Transplant. 1998; 22 1019-1021
46 Kolker O, Sviri S, Linton D M et al.. Plasmapheresis for thrombotic thrombocytopenic purpura following bone marrow transplantation. Acta Haematol. 2001; 105 156-158
47 Zeigler Z R, Shadduck R K, Nath R, Andrews III D F. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 1996; 17 81-86
48 Dua A, Zeigler Z R, Shadduck R K et al.. Apheresis in grade 4 bone marrow transplant associated thrombotic microangiopathy: a case series. J Clin Apheresis. 1996; 11 176-184
49 Silva V A, Frei-Lahr D, Brown R A, Herzig G P. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation. J Clin Apheresis. 1991; 6 16-20
50 Muller S, Schutt P, Bojko P et al.. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol. 2005; 84 110-114
51 Al-Zahrani H, Gupta V, Minden M D, Messner H A, Lipton J H. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003; 44 471-475
52 Zuber J, Martinez F, Droz D, Oksenhendler E, Legendre C. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore). 2002; 81 321-331
53 Singh N, Gayowski T, Marino I R. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int. 1996; 9 68-75
54 Reynolds J C, Agodoa L Y, Yuan C M, Abbott K C. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis. 2003; 42 1058-1068
55 Chiurchiu C, Ruggenenti P, Remuzzi G. Thrombotic microangiopathy in renal transplantation. Ann Transplant. 2002; 7 28-33
56 Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol. 2003; 18 1095-1101
57 Ducloux D, Rebibou J M, Semhoun-Ducloux S et al.. Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis. Transplantation. 1998; 65 1405-1407
58 Lahlou A, Lang P, Charpentier B et al.. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de l'Ile-de-France (GCIF). Medicine (Baltimore). 2000; 79 90-102
59 Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int. 2002; 62 1093-1104
60 Taylor C M. Complement factor H and the haemolytic uraemic syndrome. Lancet. 2001; 358 1200-1202
61 Remuzzi G, Ruggenenti P, Codazzi D et al.. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet. 2002; 359 1671-1672
62 Humar A, Jessurun J, Sharp H L, Gruessner R W. Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports. Transpl Int. 1999; 12 387-390
63 Mercadal L, Petitclerc T, Assogba U, Beaufils H, Deray G. Hemolytic and uremic syndrome after heart transplantation. Am J Nephrol. 2000; 20 418-420
64 Shitrit D, Starobin D, Aravot D et al.. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. Transplant Proc. 2003; 35 627-628
65 Fortin M C, Raymond M A, Madore F et al.. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant. 2004; 4 946-952
66 Murer L, Zacchello G, Bianchi D et al.. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol. 2000; 11 1132-1137
67 Asaka M, Ishikawa I, Nakazawa T et al.. Hemolytic uremic syndrome associated with influenza A virus infection in an adult renal allograft recipient: case report and review of the literature. Nephron. 2000; 84 258-266
68 Mor E, Lustig S, Tovar A et al.. Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection?. Transplant Proc. 2000; 32 686-687
69 McLeod B C. Thrombotic microangiopathies in bone marrow and organ transplant patients. J Clin Apheresis. 2002; 17 118-123
70 Kwaan H C, Gordon L I. Thrombotic microangiopathy in the cancer patient. Acta Haematol. 2001; 106 52-56
71 Hahn H, Ha I S, Choi H S et al.. Acute leukemia: an association with atypical hemolytic uremic syndrome. Pediatr Nephrol. 2003; 18 703-705
72 Majhail N S, Hix J K, Almahameed A. Carcinoma of the colon in a patient presenting with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Mayo Clin Proc. 2002; 77 873
73 Lee J L, Lee J H, Kim M K et al.. A case of bone marrow necrosis with thrombotic thrombocytopenic purpura as a manifestation of occult colon cancer. Jpn J Clin Oncol. 2004; 34 476-480
74 Sugimoto T, Saigo K, Shin T et al.. Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura. Acta Haematol. 2005; 113 198-203
75 Fontana S, Gerritsen H E, Kremer Hovinga J, Furlan M, Lämmle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol. 2001; 113 100-102
76 Lesesne J B, Rothschild N, Erickson B et al.. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989; 7 781-789
77 Snyder Jr H W, Mittelman A, Oral A et al.. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 1993; 71 1882-1892
78 Korec S, Schein P S, Smith F P et al.. Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol. 1986; 4 210-215
79 Borghardt E J, Kirchertz E J, Marten I, Fenchel K. Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Transfus Sci. 1998; 19(suppl) 5-7
80 Christidou F, Athanasiadou A, Kalogiannidis P et al.. Therapeutic plasma exchange in patients with grade 2-3 hematopoietic stem cell transplantation-associated thrombotic thrombocytopenic purpura: a ten-year experience. Ther Apher Dial. 2003; 7 259-262
81 Bosch T, Buhmann R, Lennertz A, Samtleben W, Kolb H J. Therapeutic plasma exchange in patients suffering from thrombotic microangiopathy after allogeneic bone marrow transplantation. Ther Apher. 1999; 3 252-256
82 Bueno Jr D, Sevigny J, Kaplan A A. Extracorporeal treatment of thrombotic microangiopathy: a ten year experience. Ther Apher. 1999; 3 294-297
83 Llamas P, Romero R, Cabrera R, Sanjuan I, Fores R, Fernandez M N. Management of thrombotic microangiopathy following allogeneic transplantation: what is the role of plasma exchange?. Bone Marrow Transplant. 1997; 20 305-306
84 Chown S R, Goulden N, Cornish J M et al.. The role of plasma exchange for TTP/HUS post-bone marrow transplant. Bone Marrow Transplant. 1996; 17 898-899

Joseph E KissM.D.

The Institute for Transfusion Medicine, 3636 Boulevard of Allies, Pittsburgh, PA 15213

eMail: jkiss@itxm.org